Protocol Ledger

NCT04421508 · Phase III · TERMINATED

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Interventional Phase III clinical trial protocol NCT04421508 sponsored by Bellerophon Pulse Technologies in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-12 Enrollment: 191 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04421508
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)191 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04421508
Protocol FieldVerified Registry Value
NCT IdentifierNCT04421508
Consolidated Lead SponsorBellerophon Pulse Technologies
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment191 participants (ACTUAL)
Registered Start Date2020-07-12
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04421508
Hospital Research SiteLocationSite Profile
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->
Temple University HospitalPhiladelphia, PAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI